In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward.

In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward.

In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.

At the Intersection of Science and Law

Life sciences companies and the risks posed by the mifepristone litigation

In this episode, Quest Diagnostics’ Adam Donat is joined by DLA Piper’s Kirsten Axelsen, Rachel Portman, and Jae Kim to discuss the increasing complexity and cost of clinical trials, new FDA guidance, innovative trial designs and tools, and what’s expected in the new year.

In this episode, Quest Diagnostics’ Adam Donat is joined by DLA Piper’s Kirsten Axelsen, Rachel Portman, and Jae Kim to discuss the increasing complexity and cost of clinical trials, new FDA guidance, innovative trial designs and tools, and what’s expected in the new year.

Revolutionizing Clinical Trials: A discussion on diversity and patient-centric approaches

DLA Piper’s Roberto Valenti and Ray Miller discuss trade secrets protection in the US and Europe and the peculiarities within the life sciences sector. Our speakers provide pragmatic approaches and suggestions on how to manage trade secrets for both pharmaceutical companies and medical device manufacturers.

DLA Piper’s Roberto Valenti and Ray Miller discuss trade secrets protection in the US and Europe and the peculiarities within the life sciences sector. Our speakers provide pragmatic approaches and suggestions on how to manage trade secrets for both pharmaceutical companies and medical device manufacturers.

Trade secrets protection in the life sciences sector

Published in Chambers Expert Focus. With the recent publication of our Cross-border Guide to Clinical Trials and Privacy, James Clark, Paula Gonzalez de Castejón and David Kopans discuss ongoing and developing EU and US perspectives on privacy considerations with respect to cross-border clinical trials.

<a href="https://chambers.com/legal-trends/cross-border-considerations-for-privacy-in-clinical-trials">Published in Chambers Expert Focus.</a> With the recent publication of our Cross-border Guide to Clinical Trials and Privacy, James Clark, Paula Gonzalez de Castejón and David Kopans discuss ongoing and developing EU and US perspectives on privacy considerations with respect to cross-border clinical trials.

Life sciences companies and the risks posed by the mifepristone litigation

At the Intersection of Science and Law

In 1 playlist(s)

At the Intersection of Science and Law

Social links

Follow podcast

Recent clips